Segall Bryant & Hamill LLC Takes Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Segall Bryant & Hamill LLC bought a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 58,411 shares of the company’s stock, valued at approximately $297,000. Segall Bryant & Hamill LLC owned about 0.20% of Eliem Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Rhumbline Advisers bought a new position in shares of Eliem Therapeutics in the second quarter valued at approximately $59,000. SG Americas Securities LLC bought a new position in Eliem Therapeutics in the 3rd quarter worth approximately $60,000. Dimensional Fund Advisors LP bought a new position in Eliem Therapeutics in the 2nd quarter worth approximately $89,000. Chicago Partners Investment Group LLC bought a new position in Eliem Therapeutics in the 3rd quarter worth approximately $81,000. Finally, Bank of New York Mellon Corp bought a new position in Eliem Therapeutics in the 2nd quarter worth approximately $134,000. Institutional investors own 69.76% of the company’s stock.

Eliem Therapeutics Price Performance

ELYM stock opened at $5.11 on Monday. The company has a 50 day moving average price of $4.89 and a 200 day moving average price of $6.56. Eliem Therapeutics, Inc. has a fifty-two week low of $2.35 and a fifty-two week high of $11.55. The stock has a market capitalization of $152.03 million, a PE ratio of -5.75 and a beta of -0.39.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.